NICE technology appraisal guidance (TA1026) covers its use for weight management in England, again subject to eligibility criteria, specialist service referral, and local commissioning and supply [16] Orlistat an older, orally administered option available on NHS prescription in primary care Access to GLP-1 and dual agonist therapies for weight management is currently via specialist services and remains subject to NICE criteria, local commissioning decisions, and ongoing supply considerations
Laboratory evaluation typically includes complete blood count to assess for anemia and determine acuity of blood loss, comprehensive metabolic panel to evaluate renal function and electrolytes (particularly relevant given tirzepatide's gastrointestinal effects), and coagulation studies if bleeding disorder is suspected
Food & Drug Administration (FDA) labels, but others arent
While telehealth may increase access to treatment, some healthcare providers caution that virtual care works best when combined with traditional office visits
References van der Kolk JH, Thomas S, Mach N, Ramseyer A, Burger D, Gerber V, Nuoffer JM